PDS Biotechnology (PDSB) Stock Price, News & Analysis

Company Overview

PDS Biotechnology Corporation (NASDAQ: PDSB) is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer and infectious diseases. The company’s technology is designed to stimulate the immune system and generate antigen-specific T-cell responses against diseased cells.

PDS Biotech’s lead investigational product is PDS0101, an immunotherapy designed to target human papillomavirus type 16 (HPV16) antigens E6 and E7. The product is being evaluated in combination with other treatments for HPV16-associated cancers, including cervical, anal, and certain head and neck cancers. The company is also advancing additional vaccine and immunotherapy candidates based on its Versamune platform.

Founded in 2005 and headquartered in Florham Park, New Jersey, PDS Biotech conducts development activities through clinical research programs and collaborations. Its programs are investigational and remain subject to clinical testing and regulatory review. The company is led by President and Chief Executive Officer Frank Bedu-Addo.

Key Stats

• Today's Range: $1.45 to $1.67
• 50-Day Range: $0.20 to $1.60
• 52-Week Range: $0.20 to $1.79
• Volume: 5.78 million shs
• Average Volume: 8.34 million shs
• Market Capitalization: $82.28 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Hold

PDS Biotechnology Stock Analysis - MarketRank™

PDS Biotechnology scored higher than 65% of companies evaluated by MarketBeat, and ranked 338th out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

PDS Biotechnology has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

PDS Biotechnology has a consensus price target of $9.00, representing about 513.1% upside from its current price of $1.47.

Amount of Analyst Coverage

PDS Biotechnology has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for PDS Biotechnology are expected to grow in the coming year, from ($0.47) to ($0.34) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of PDS Biotechnology is -2.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of PDS Biotechnology is -2.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

PDS Biotechnology has a P/B Ratio of 8.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.40% of the float of PDS Biotechnology has been sold short.

Short Interest Ratio / Days to Cover

PDS Biotechnology has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in PDS Biotechnology has recently decreased by 56.76%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

PDS Biotechnology does not currently pay a dividend.

Dividend Growth

PDS Biotechnology does not have a long track record of dividend growth.

News and Social Media

• Score: 4.0 / 5
• News Sentiment: 1.34

News Sentiment

PDS Biotechnology has a news sentiment score of 1.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for PDS Biotechnology this week, compared to 2 articles on an average week.

Search Interest

24 people have searched for PDSB on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, PDS Biotechnology insiders have not sold or bought any company stock.

Percentage Held by Insiders

8.40% of the stock of PDS Biotechnology is held by insiders.

Percentage Held by Institutions

26.84% of the stock of PDS Biotechnology is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/14/2026
• KOL event: 10/15/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:PDSB
• CIK: 1472091
• Web: www.pdsbiotech.com
• Phone: (800) 208-3343
• Fax: 908-790-1212
• Employees: 21
• Year Founded: 2005

Price Target and Rating

• Average Price Target for PDS Biotechnology: $9.00
• High Price Target: $15.00
• Low Price Target: $3.00
• Potential Upside/Downside: +506.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$34.50 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -708.18%
• Return on Assets: -136.50%

Debt

• Debt-to-Equity Ratio: 2.73
• Current Ratio: 0.57
• Quick Ratio: 0.57

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.18 per share
• Price / Book: 8.25

Miscellaneous

• Outstanding Shares: 55,970,000
• Free Float: 51,269,000
• Market Cap: $83.12 million
• Optionable: Optionable
• Beta: 1.17